Licensing Opportunity Yamo's L1-79 has shown positive Phase 2 results for autism, with a mechanism that targets CNS and metabolic symptoms. As a tiny team operating in NYC, they are likely seeking strategic collaborations to advance to late-stage trials and commercialization. This makes licensing out or co-development discussions a strong sales opportunity for larger pharma or biotech partners.

Trial Outsourcing Given the company size, they will rely on CROs and external vendors to run clinical trials, data management, and analytics as they scale. This creates a clear opening for end-to-end trial partnerships, patient recruitment networks, endpoint validation, and pharmacovigilance services—especially for potential Phase 3 activities.

Regulatory Readiness Progression to later-stage development will require regulatory guidance, CMC development, and manufacturing scale-up. Yamo may be planning regulatory filings and GMP manufacturing partnerships, so offering regulatory affairs consulting, quality systems support, and scalable manufacturing solutions could be a strong fit.

Funding Alignment With modest revenue and a lean team, Yamo may pursue funding partnerships or licensing deals to accelerate development while maintaining capital efficiency. This positions them as a candidate for strategic investments, milestone-based co-development financing, or in-licensing opportunities from investors or larger players.

Market Positioning L1-79's differentiated mechanism for core ASD symptoms positions it in a potentially attractive segment, augmented by recent INSAR momentum. This suggests opportunities for market access planning, payer strategy, and collaboration with autism research consortia, academic partners, and patient advocacy groups to build evidence and drive adoption.